[en] Purpose From epidemiological studies it appears that breast cancer (BC) and cutaneous melanoma (CMM) in the same individual occur at a higher frequency than expected by chance. Genetic factors common to both cancers can be suspected. Our goal was to estimate the involvement of "high risk" genes in patients presenting these two neoplasia, selected irrespectively from family history and age at diagnosis. Experimental Design Eighty two patients with BC and CMM were screened for BRCA1, BRCA2, TP53, CDKN2A and CDK4 (exon 2) germline mutations. Results Deleterious mutations were identified in 6 patients: two carriers of a BRCA1 germline mutation, two carriers of TP53 germline mutations (one of which also harbored a BRCA2 deleterious mutation, the other one a BRCA2 unclassified variant), and two carriers of a CDKN2A germline mutation. In addition, 6 variants of unknown signification were identified in BRCA1 or BRCA2 genes. Regarding family history, 3/13 (23%) patients with a positive family history of BC or CMM were carriers of a germline mutation, whereas only 3/69 (4%) patients without family history were carriers of a germline mutation. Conclusion Our findings show that few patients with BC and CMM who lacked family histories of these cancers are carriers of deleterious germline mutations in four of the five genes we examined. We describe for the first time, two simultaneous BRCA2 and TP53 mutations, suggesting that analysis in more than one gene could be performed if a patient's personal or familial history does not match a single syndrome.
Disciplines :
Genetics & genetic processes Oncology
Author, co-author :
Monnerat, C.
Chompret, A.
Kannengiesser, C.
Avril, M. F.
Janin, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Spatz, A.
Guinebretiere, J. M.
Marian, C.
Barrois, M.
Boitier, F.
Lenoir, G. M.
Paillerets, B. B. D.
Language :
English
Title :
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
Mellemkjaer L, Friis S, Olsen JH et al (2005) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285-2292
Volk N, Pompe-Kirn V (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8:764-770
Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:99-112
Ewertz M, Mouridsen HT (1985) Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 68:325-329
Rubino C, De Vathaire F, Diallo I et al (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61:183-195
Schwartz AG, Ragheb NE, Swanson GM et al (1989) Racial and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res Treat 14:245-254
Lavey RS, Eby NL, Prosnitz LR (1990) Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 66:874-881
Doherty MA, Rodger A, Langlands AO et al (1993) Multiple primary tumours in patients treated with radiotherapy for breast cancer. Radiother Oncol 26:125-131
Levi F, La Vecchia C, Randimbison L et al (1997) Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer 72:776-779
Retsas S, Mohith A, Bell J et al (2000) Melanoma and additional primary cancers. Melanoma Res 10:145-152
Gutman M, Cnaan A, Inbar M et al (1991) Are malignant melanoma patients at higher risk for a second cancer? Cancer 68:660-665
Wassberg C, Thorn M, Yuen J et al (1996) Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer 73:255-259
Swerdlow AJ, Storm HH, Sasieni PD (1995) Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61:773-779
Goggins W, Gao W, Tsao H (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111(5):792-794
Greene MH, Fraumeni JF (1979) The hereditary variant of farnilial melanoma. In: Clark WH Jr., Goldman LI, Mastrangelo MJ (eds) Human malignant melanoma. Grune and Stratton, New York, pp 139-166
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet (2001) 358:1389-1399
Hussussian CJ, Struewing JP, Goldstein AM et al (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15-21
Zuo L, Weger J, Yang Q et al (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792
Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
Chompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932-1937
Olivier M, Goldgar DE, Sodha N et al (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650
Borg A, Sandberg T, Nilsson K et al (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260-1266
Ghiorzo P, Ciotti P, Mantelli M et al (1999) Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83:441-448
Cancer risks in BRCA2 mutation carriers (1999) The breast cancer linkage consortium. J Natl Cancer Inst 91:1310-1316
Eisinger F, Alby N, Bremond A et al (1998) Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 9:939-950
Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439-474
Flaman JM, Robert V, Lenglet S et al (1998) Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 16:1369-1372
Bignell G, Micklem G, Stratton MR et al (1997) The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet 6:53-58
Wu K, Hinson SR, Ohashi A et al (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65:417-426
Kefford RF, Newton Bishop JA, Bergman W et al (1999) Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17:3245-3251
Soufir N, Avril MF, Chompret A et al (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209-216
Fackenthal JD, Cartegni L, Krainer AR et al (2002) BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71:625-631
Mayer K, Ballhausen W, Leistner W et al (2000) Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochim Biophys Acta 1502:495-507
Harland M, Mistry S, Bishop DT et al (2001) A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10:2679-2686
Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365
Ramus SJ, Friedman LS, Gayther SA et al (1997) A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 15:14-15
Moslehi R, Russo D, Phelan C et al (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet 57:70-73
Tesoriero A, Andersen C, Southey M et al (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567-569
Borg A, Isola J, Chen J et al (2000) Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer 85:796-800
Reifenberger J, Arnold N, Kiechle M et al (2001) Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. J Invest Dermatol 116:472-474
Ramus SJ, Bobrow LG, Pharoah PD et al (1999) Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 25:91-96
Jonkers J, Meuwissen R, van der Gulden H et al (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29:418-425
Gadd M, Pisc C, Branda J et al (2001) Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution. Cancer Res 61:8811-8819
Haraldsson K, Loman N, Zhang QX et al (1998) BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367-1371
Bishop DT, Demenais F, Goldstein AM et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894-903
Auroy S, Avril MF, Chompret A et al (2001) Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32:195-202
Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37:828-830
